Does Aetna Cover Weight Loss Treatment in New Hampshire? A 2026 Guide

Last updated: July 18, 2026

If you have Aetna health insurance in New Hampshire and you are exploring weight loss treatment options. Including GLP-1 medications like Wegovy or Zepbound, older appetite suppressants, or behavioral programs. This guide breaks down what Aetna may cover, how CVS/Caremark formulary tiers apply, and what New Hampshire’s Electronic Prescribing of Controlled Substances (EPCS) law means for weight loss prescriptions in 2026.

Key Facts. Aetna Weight Loss Coverage in New Hampshire (2026)

• Insurer: Aetna Health Inc. (commercial plans)
• PBM: CVS/Caremark
• 2026 Formulary update: Zepbound (tirzepatide) reinstated on CVS/Caremark commercial formularies effective October 1, 2026
• NH EPCS law: RSA 318-B:21-a. Schedule II. V. Phentermine and Qsymia (Schedule IV) require electronic prescribing in NH
• GLP-1s, Contrave, orlistat: Non-scheduled. EPCS entirely inapplicable
• NH parity law: RSA 417-E:1 covers mental health and substance use disorders only. Does NOT govern weight loss medications
• Medicare GLP-1 Bridge: Applies to Medicare Advantage only. Not applicable to Aetna commercial plans
• Member services: 1-800-872-3862
• CVS/Caremark: 1-800-552-8159
• NH Insurance Department: 1-800-852-3416

Weight loss treatment through Aetna in New Hampshire may include FDA-approved medications, behavioral counseling, and nutritional programs depending on your specific plan. Coverage details vary by plan type. Fully insured, self-funded, or ACA marketplace. So verifying your benefits before starting treatment is essential.

See if you may qualify for weight loss treatment through Klarity Health. Klarity has 2,000+ licensed providers who may be able to evaluate and treat weight loss conditions online in New Hampshire. Check your options at Klarity Health →

Zepbound Reinstated on CVS/Caremark: What It Means for Aetna Members in New Hampshire

One of the most significant formulary developments for Aetna members in 2026 is the reinstatement of Zepbound (tirzepatide) on CVS/Caremark commercial formularies, effective October 1, 2026. CVS Health announced this change in May 2026, reversing the earlier removal of Zepbound and Wegovy from some CVS/Caremark commercial formulary tiers.

For Aetna members in New Hampshire whose plans use CVS/Caremark as their pharmacy benefit manager:

• Zepbound may return to Tier 3 or Tier 4 status on applicable commercial formularies beginning October 1, 2026
• Prior authorization will still typically be required for Zepbound (BMI ≥30, or ≥27 with a qualifying comorbidity such as type 2 diabetes, hypertension, or dyslipidemia)
• Wegovy (semaglutide) similarly remains on CVS/Caremark commercial formularies at Tier 3. 4 with PA requirements
• Members who were previously denied or had coverage discontinued should re-verify their benefits after October 1, 2026

This reinstatement is distinct from the Medicare GLP-1 Bridge program launched July 1, 2026, which applies only to Medicare Advantage plans. Aetna commercial members in New Hampshire are not covered by the Medicare bridge program.

CVS/Caremark Weight Loss Formulary for Aetna Members. New Hampshire 2026

Aetna uses CVS/Caremark as its pharmacy benefit manager for most commercial plans in New Hampshire. The table below reflects typical CVS/Caremark commercial formulary tiers and NH EPCS status for weight loss medications. Always verify your specific plan’s current formulary at aetna.com or by calling CVS/Caremark at 1-800-552-8159.

Formulary tiers are representative of CVS/Caremark commercial formularies and may vary by plan year, employer group, and ACA vs. commercial plan type. Verify at aetna.com or by calling 1-800-872-3862.

New Hampshire EPCS Law and Weight Loss Prescriptions

New Hampshire’s Electronic Prescribing of Controlled Substances law, codified at RSA 318-B:21-a, requires electronic prescribing for all controlled substances in Schedules II through V. This is a broad mandate that extends beyond the federal DEA requirement (21 CFR § 1311) and beyond the laws of many other states.

How EPCS applies to weight loss medications in New Hampshire:

Phentermine and Qsymia. EPCS REQUIRED

Phentermine (standalone, as in Adipex-P) and phentermine/topiramate ER (Qsymia) are both classified as Schedule IV controlled substances under the federal Controlled Substances Act. Because RSA 318-B:21-a covers Schedules II through V, prescribers in New Hampshire must use an EPCS-certified platform to prescribe these medications. Paper or fax prescriptions are not permitted for Schedule IV substances in NH.

GLP-1 Medications, Contrave, and Orlistat. EPCS Inapplicable

GLP-1 receptor agonists (Wegovy, Zepbound, Saxenda), the combination naltrexone/bupropion product Contrave, and orlistat (Xenical, Alli) are not scheduled under the Controlled Substances Act. RSA 318-B:21-a has no applicability to these medications. Prescribers may use electronic, paper, or telephone prescriptions for GLP-1s and Contrave per standard NH prescribing rules.

NH vs. Hawaii. EPCS Comparison for Weight Loss Drugs

The key takeaway: if you are prescribed phentermine or Qsymia in New Hampshire, your provider must use an EPCS-certified system. If you are seeing a telehealth provider based in another state, confirm they are EPCS-compliant for New Hampshire prescribing before your visit.

Does RSA 417-E:1 (NH Mental Health Parity) Apply to Weight Loss Coverage?

New Hampshire’s mental health parity statute, RSA 417-E:1 et seq., requires that fully insured commercial health plans cover mental health and substance use disorder benefits at parity with medical and surgical benefits. This law is enforced by the NH Insurance Department and supplements the federal Mental Health Parity and Addiction Equity Act (MHPAEA).

RSA 417-E:1 does NOT govern weight loss medications or obesity treatment. Weight loss is not classified as a mental health or substance use disorder under RSA 417-E:1, nor under the federal MHPAEA framework. Coverage for GLP-1 medications, phentermine, and other weight loss drugs is governed by:

• ACA Essential Health Benefits (EHB). For individual and small group plans sold in NH, which set minimum coverage floors for preventive services and some chronic condition management
• ERISA. For self-funded employer plans, which are federally regulated and not subject to NH state insurance mandates
• Plan contract terms. For large group fully insured plans, which may include or exclude weight loss drugs based on benefit design elections

If you believe your Aetna plan has wrongly denied weight loss coverage, contact the NH Insurance Department at 1-800-852-3416 to file a complaint or request assistance with an appeal.

Medicare GLP-1 Bridge: Does It Apply to Aetna Commercial Members?

Effective July 1, 2026, CMS launched a Medicare GLP-1 Bridge program allowing eligible Medicare Advantage Part D members to access Wegovy, Zepbound, and Foundayo (semaglutide subcutaneous) at $50 per month, funded through the Medicare program regardless of their plan’s Part D formulary.

This program does NOT apply to Aetna commercial insurance members in New Hampshire. The Medicare GLP-1 Bridge is exclusively available to Medicare Advantage (Part D) enrollees. Aetna commercial plans. Including those purchased through the ACA marketplace, through an employer, or directly from Aetna. Are not covered by the CMS bridge program.

Aetna commercial members in NH who want GLP-1 coverage should verify their benefits directly with Aetna at 1-800-872-3862 or through CVS/Caremark at 1-800-552-8159, particularly in light of the October 1, 2026 Zepbound reinstatement.

Prior Authorization Process for Weight Loss Medications

Aetna and CVS/Caremark require prior authorization for most GLP-1 weight loss medications. Understanding the PA process can help reduce delays:

Common PA Criteria for GLP-1 Medications (Wegovy, Zepbound)

• BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one weight-related comorbidity (e.g., type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
• Documentation that the member is enrolled in or willing to participate in a comprehensive lifestyle modification program
• Prescriber attestation that the medication is being used for obesity management (not diabetes management, which has separate criteria)
• Step therapy may be required on some plans. Prior failure on an older agent such as orlistat or phentermine/topiramate

Submitting a PA Request

• Electronic PA: Submit through Availity (availity.com). Preferred by Aetna for all PA requests
• Provider portal: aetna.com/providers offers PA submission and tracking
• Fax: Available as a fallback. Contact Aetna provider services for current fax numbers
• Timeframes: Standard PA decisions within 72 hours (3 business days); urgent PA within 24 hours

Appealing a Denial

If your PA is denied, Aetna must provide a written explanation of the denial and information about your right to appeal. Steps:

1. Request a first-level internal appeal within 180 days of denial
2. If denied again, request an external review by an independent review organization (IRO)
3. Contact the NH Insurance Department at 1-800-852-3416 if you need assistance filing a complaint or navigating the appeal process

What Weight Loss Treatments May Aetna Cover in New Hampshire?

Beyond prescription medications, Aetna may cover additional weight loss services in New Hampshire:

Behavioral and Lifestyle Programs

• Obesity counseling: ACA-compliant plans are required to cover intensive behavioral counseling for obesity as a preventive service for adults with BMI ≥ 30 at no cost-sharing
• Nutritional counseling: Medical nutrition therapy may be covered when ordered by a physician for diagnosed obesity or related conditions (e.g., type 2 diabetes)
• Telehealth weight loss visits: RSA 415-J:2 requires NH-regulated plans to provide telehealth coverage at parity with in-person services for covered benefits

Bariatric Surgery

Some Aetna commercial plans in New Hampshire may cover bariatric surgery (gastric bypass, sleeve gastrectomy) for severe obesity. Typical criteria include BMI ≥ 40, or BMI ≥ 35 with serious comorbidities, plus documented failure of conservative weight loss attempts. Check your specific plan documents or call Aetna at 1-800-872-3862.

Qualifying Medical Criteria for Weight Loss Coverage

• Diagnosed obesity (BMI ≥ 30 for most medications; BMI ≥ 27 for GLP-1s with comorbidities)
• At least one weight-related comorbidity (type 2 diabetes, hypertension, hyperlipidemia, obstructive sleep apnea, PCOS, cardiovascular disease)
• Documentation of physician-supervised weight management attempts for bariatric surgery candidates

How to Verify Your Aetna Weight Loss Coverage in New Hampshire

Before starting any weight loss treatment, take these steps to verify your specific Aetna benefits:

1. Log in to your Aetna member portal at aetna.com/members. Review your plan’s drug formulary under “Pharmacy Benefits” and search for your specific medication by name or drug class.
2. Call Aetna member services: 1-800-872-3862. Ask specifically whether your medication requires PA, what tier it is on, and what your cost-sharing will be.
3. Call CVS/Caremark: 1-800-552-8159. As Aetna’s PBM, CVS/Caremark can confirm formulary tier, PA requirements, and whether your pharmacy is in-network.
4. Ask your provider to check: Your prescribing provider can submit a PA inquiry through Availity before prescribing to confirm coverage and avoid claim denials.
5. Review your plan’s Summary of Benefits and Coverage (SBC): Available from your employer benefits portal or at aetna.com. The SBC outlines which services require PA and what your deductible and out-of-pocket costs are.

Klarity Health: Weight Loss Treatment in New Hampshire

Klarity Health connects New Hampshire residents with licensed providers who may be able to evaluate and treat weight loss conditions via telehealth. With 2,000+ licensed providers across the country, Klarity offers convenient online appointments for weight loss evaluation, medication management, and ongoing care.

Klarity providers are familiar with EPCS requirements, including New Hampshire’s RSA 318-B:21-a mandate, and can prescribe electronically where applicable. Coverage varies by plan, and Klarity Health encourages all patients to verify their insurance benefits before booking.

Check if your plan may cover weight loss treatment through Klarity Health. See weight loss treatment options at Klarity Health →

Frequently Asked Questions

Does Aetna cover Wegovy in New Hampshire in 2026?

Wegovy (semaglutide) may be covered under some Aetna commercial plans in New Hampshire. It is typically placed at Tier 3. 4 on CVS/Caremark formularies and usually requires prior authorization based on BMI criteria. Coverage varies by plan type. Verify with Aetna at 1-800-872-3862 or CVS/Caremark at 1-800-552-8159.

Is Zepbound covered by Aetna in New Hampshire after the October 2026 reinstatement?

Zepbound (tirzepatide) was reinstated on CVS/Caremark commercial formularies effective October 1, 2026. Aetna commercial plan members who use CVS/Caremark as their PBM may find Zepbound on their formulary beginning October 1, 2026, typically at Tier 3. 4 with prior authorization. Check your plan’s specific formulary after that date.

Does phentermine require an electronic prescription in New Hampshire?

Yes. Phentermine is a Schedule IV controlled substance, and New Hampshire’s RSA 318-B:21-a requires electronic prescriptions for all Schedule II. V substances. Prescribers must use an EPCS-certified platform. Paper or fax prescriptions for phentermine are not permitted in NH.

Does NH RSA 417-E:1 require Aetna to cover weight loss medications?

No. RSA 417-E:1 is New Hampshire’s mental health parity law. It covers mental health and substance use disorder benefits only. It does not require coverage of weight loss medications or obesity treatment. Coverage for weight loss drugs is governed by ACA Essential Health Benefits rules (for ACA plans) and individual plan contract terms (for employer plans).

Does the Medicare GLP-1 Bridge ($50/month) apply to Aetna commercial plans in NH?

No. The CMS Medicare GLP-1 Bridge program that launched July 1, 2026 applies only to Medicare Advantage Part D enrollees. Aetna commercial insurance members. Including ACA marketplace, employer, and individual plans. Are not eligible for the Medicare bridge program.

How do I appeal an Aetna denial for weight loss medication?

Request a written denial notice from Aetna explaining the reason for denial. You have 180 days to file a first-level internal appeal. If the internal appeal is denied, you may request external review by an independent review organization (IRO). For assistance, contact the NH Insurance Department at 1-800-852-3416.

Key Contacts

• Aetna Member Services: 1-800-872-3862
• CVS/Caremark (PBM): 1-800-552-8159
• NH Insurance Department: 1-800-852-3416
• Aetna PA portal: Availity (availity.com) / aetna.com/providers
• CMS Medicare Helpline: 1-800-633-4227

Disclaimer: Coverage details on this page are for general informational purposes only and reflect typical CVS/Caremark formulary structures and Aetna commercial plan patterns as of July 2026. Actual coverage depends on your specific plan documents, employer benefit design, and plan year. Always verify your benefits directly with Aetna and CVS/Caremark before starting any treatment. Nothing on this page constitutes medical or legal advice. The NH Insurance Department (1-800-852-3416) can assist with coverage disputes and complaints.